Literature DB >> 26003802

IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties.

Jagadeesh Bayry1, Hans-Peter Hartung2, Srini V Kaveri3.   

Abstract

Despite promising clinical trials, intravenous immunoglobulin (IVIg) therapy in relapsing-remitting multiple sclerosis (MS) has met with uncertainties that might be attributed to small patient cohorts, heterogeneity in the patients, dose of IVIg, or the duration and window of treatment.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  IVIg; autoimmunity; biomarkers; immunotherapy; inflammation; multiple sclerosis

Mesh：

Substances：

Year:  2015        PMID： 26003802     DOI： 10.1016/j.tips.2015.04.012

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN： 0165-6147            Impact factor:   14.819


  6 in total

1.  Cost-Effectiveness of Repository Corticotropin Injection for the Treatment of Acute Exacerbations in Multiple Sclerosis.

Authors:  Samuel F Hunter; Jas Bindra; Ishveen Chopra; John Niewoehner; Mary P Panaccio; George J Wan
Journal:  Clinicoecon Outcomes Res       Date:  2021-10-11

Review 2.  Therapeutic Potential of Intravenous Immunoglobulin in Acute Brain Injury.

Authors:  Vivien Thom; Thiruma V Arumugam; Tim Magnus; Mathias Gelderblom
Journal:  Front Immunol       Date:  2017-07-31       Impact factor: 7.561

3.  Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.

Authors:  Mohan S Maddur; Emmanuel Stephen-Victor; Mrinmoy Das; Praveen Prakhar; Varun K Sharma; Vikas Singh; Magalie Rabin; Jamma Trinath; Kithiganahalli N Balaji; Francis Bolgert; Jean-Michel Vallat; Laurent Magy; Srini V Kaveri; Jagadeesh Bayry
Journal:  J Neuroinflammation       Date:  2017-03-20       Impact factor: 8.322

4.  Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.

Authors:  Caroline Galeotti; Pushpa Hegde; Mrinmoy Das; Emmanuel Stephen-Victor; Fernando Canale; Marcos Muñoz; Varun K Sharma; Jordan D Dimitrov; Srini V Kaveri; Jagadeesh Bayry
Journal:  Sci Rep       Date:  2016-01-22       Impact factor: 4.379

5.  Healthcare Costs and Resource Utilization in Patients with Multiple Sclerosis Relapses Treated with H.P. Acthar Gel(®).

Authors:  Laura S Gold; Kangho Suh; Patricia B Schepman; Kavitha Damal; Ryan N Hansen
Journal:  Adv Ther       Date:  2016-06-17       Impact factor: 3.845

Review 6.  The Homophilic Domain - An Immunological Archetype.

Authors:  Heinz Kohler; Jagadeesh Bayry; Srinivas V Kaveri
Journal:  Front Immunol       Date:  2016-03-21       Impact factor: 7.561
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.